Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis

Hepatology Research

Volumn 38, Issue 2, 2008, Pages 159-165

  de Oliveira, Claudia Pinto Marques Souza ^a   Stefano, José Tadeu ^a   De Siqueira, Erika Rabelo Forte ^a   Silva, Leonardo Soares ^a   de Campos Mazo, Daniel Ferraz ^a   Lima, Vicência Mara Rodrigues ^a   Furuya, Carlos Kioshi ^a   Mello, Evandro Sobroza ^a   Souza, Fabrício G ^a   Rabello, Fabíola ^a   Santos, Telma Eugênio ^a   Nogueira, Monize Aydar ^a   Caldwell, Stephen H ^b   Alves, Venâncio Avancini Ferreira ^a   Carrilho, Flair José ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Metformin; N acetylcysteine; Non alcoholic steatohepatitis; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; LOW CALORY DIET; MALE; NONALCOHOLIC FATTY LIVER; NUTRITIONAL STATUS; PILOT STUDY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 38049131878     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00215.x     Document Type: Article

References (43)

1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5-10.
2. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40: S17-29.
3. Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol 2005; 42: S2-12.
4. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.
5. Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterol 2002; 97: 2058-62.
6. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
7. Ong J, Younossi ZM, Reddy V et al. Cryptogenic cirrhosis and post transplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
9. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
10. Marchesini G, Bugianesi E. NASH as part of the metabolic (insulin resistance) syndrome. In: Farrell GC, George J, Hall PM, McCullough AJ, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005; 55-65.
11. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-97.
12. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
13. Uesugi T, Froh M, Arteel GE et al. Role of lipopolysaccharide-binding protein in early alcohol-induced liver injury in mice. J Immunol 2002; 168: 2963-9.
14. Kooby DA, Fong Y, Suriawinata A et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-44.
15. den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: A mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004; 24: 644-9.
16. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
17. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G193-9.
18. Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: Mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 2003; 4: 487-92.
19. Tripathy D, Mohanty P, Dhindsa S et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-7.
20. Jansen PL. Nonalcoholic steatohepatitis. Neth J Med 2004; 62: 217-24.
21. Uygun A, Kadayifci A, Yesilova Z et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-9.
22. Ailhaud G, Teboul M, Massiera F. Angiotensinogen, adipocyte differentiation and fat mass enlargement. Curr Opin Clin Nutr Metab Care 2002; 5: 385-9.
23. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
24. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: Pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-93.
25. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
26. Cotgreave IA. N-acetylcysteine: Pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997; 38: 205-27.
27. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998; 92: 609-23.
28. Gruady SM, Hansen B, Smith SC Jr etal. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-6.
29. Kleiner DE, Brunt EM, Van Natta ML et al. Design and validation of a histologic scoring system for NAFLD. Hepatology 2005; 41: 1313-21.
30. De Rosa SC, Zaretsky MD, Dubs JG et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30: 915-29.
31. Sochman JW N-acetylcysteine in acute cardiology: 10years later: what do we know and what would we like to know? J Am Coll Cardiol 2002; 39: 1422-8.
32. Rota C, Bergamini S, Daneri F, Tomasi A, Virgili F, Iannone A. N-acetylcysteine negatively modulates nitric oxide production in endotoxin-treated rats through inhibition of NF-kappaB activation. Antioxid Redox Signal 2002; 4: 221-6.
33. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18: 1214-24.
34. Gulbahar O, Karasu ZA, Ersoz G, Akarca US. Treatment of nonalcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000; 118: 1444.
35. Suzuki A, Lymp J, Sauver JS, Angulo P, Lindor K. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. Liver Int 2006; 26: 1209-16.
36. Uygun A, Kadayifci A, Isik AT et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-44.
37. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
38. Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90.
39. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-4.
40. Oliveira CPMS, Furuya CK Jr, Souza FG et al. N-acetilcysteine (NAC) not improves inflammation and fibrosis in patients with nonalcoholic steatohepatitis [Abstract]. Gastroenterology 2005; 128: A-769.
41. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004; 20: 623-8.
42. Lindor KD, Kowdley KV, Heathcote EJ et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial. Hepatology 2004; 39: 770-8.
43. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24: 3-20.